LONGEVA.

NMN: adverse events in a trial

A 12-week oral NMN trial in 30 healthy adults recorded adverse events in 8 of 15 NMN participants and 7 of 15 placebo participants, with none serious. Investigators attributed one brief episode of abdominal pain to NMN. The event totals do not mean that NMN caused every event. [1]

This small, short trial does not establish rare or lasting risks, safety by other routes, or safety of a particular laboratory reagent batch. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events overall30 healthy adults, oral NMN for 12 weeks (15 in the NMN group, 15 on placebo)Recorded in 8 of 15 NMN participants and 7 of 15 placebo participants; the event totals do not mean that NMN caused every event[1]
Brief abdominal painThe NMN group in the same trialOne episode, attributed to NMN by the investigators[1]
Serious eventsThe same participantsNone[1]

References

  1. Okabe K et al. (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.